Federal Register - August 10, 2021
Versión en texto ¿Qué es?Dateas es un sitio independiente no afiliado a entidades gubernamentales. La fuente de los documentos PDF aquí publicados es la entidad gubernamental indicada en cada uno de ellos. Las versiones en texto son transcripciones no oficiales que realizamos para facilitar el acceso y la búsqueda de información, pero pueden contener errores o no estar completas.
Fuente: Federal Register
43670
Federal Register / Vol. 86, No. 151 / Tuesday, August 10, 2021 / Notices
Title 5, U.S.C., section 4314 c 4, which requires that members of performance review boards be appointed in a manner to ensure consistency, stability, and objectivity in performance appraisals and requires that notice of the appointment of an individual to serve as a member be published in the Federal Register.
The following persons will serve on the NIH Performance Review Board, which oversees the evaluation of performance appraisals of NIH Senior Executive Service SES members:
Alfred Johnson, Chair Courtney Billet Michael Gottesman Darla Hayes Michael Lauer Kathleen Stephan Lawrence Tabak
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health Prospective Grant of an Exclusive Patent License: Multi-Domain Amphipathic Helical Peptide for Use as A Human Therapeutic in Patients With Atherosclerotic Cardiovascular Disease, Including Patients Undergoing Cardiovascular Surgery Who Are at risk of Acute Kidney Injury AGENCY:
FR Doc. 202117039 Filed 8921; 8:45 am BILLING CODE 414001P
jbell on DSKJLSW7X2PROD with NOTICES
E11420040
US01.
E11420040
PCT02.
E11420040
AU03.
E11420040
CA04.
E11420040
EP05.
E11420040
JP06.
E11420040
US07.
E11420040
US08.
E11420040
US09.
E11420040
CH11.
E11420040
DE12.
E11420040
ES13.
E11420040
FR14.
E11420040
GB15.
E11420040
IT16.
E11420040
US17.
VerDate Sep<11>2014
Patent Application No.
Title Multi-Domain Amphipathic ods Of Their Use.
Multi-Domain Amphipathic ods Of Their Use.
Multi-Domain Amphipathic ods Of Their Use.
Multi-Domain Amphipathic ods Of Their Use.
Multi-Domain Amphipathic ods Of Their Use.
Multi-Domain Amphipathic ods Of Their Use.
Multi-Domain Amphipathic ods Of Their Use.
Multi-Domain Amphipathic ods Of Their Use.
Multi-Domain Amphipathic ods Of Their Use.
Multi-Domain Amphipathic ods Of Their Use.
Multi-Domain Amphipathic ods Of Their Use.
Multi-Domain Amphipathic ods Of Their Use.
Multi-Domain Amphipathic ods Of Their Use.
Multi-Domain Amphipathic ods Of Their Use.
Multi-Domain Amphipathic ods Of Their Use.
Multi-Domain Amphipathic ods Of Their Use.
All U.S. and foreign patents and applications claiming priority to any member of the above.
The patent rights in these inventions have been assigned or exclusively
17:05 Aug 09, 2021
Jkt 253001
section of this notice. This is a first notice intended to apprise the public of a change in prospective licensee of the subject intellectual property rights in the stated field of use.
Only written comments and/or applications for a license which are received by the National Heart, Lung, and Blood Institute on or before August 25, 2021 will be considered.
DATES:
Requests for copies of the patent application, inquiries, and ACTION: Notice.
comments relating to the contemplated an exclusive patent license should be SUMMARY: The National Heart, Lung, and directed to: Michael Davis, J.D., Ph.D., Blood Institute, an institute of the Senior Technology Transfer Manager, 31
National Institutes of Health, Center Drive Room 4A29, MSC2479, Department of Health and Human Bethesda, MD 208922479, phone Services, is contemplating the grant of number 3014519032, or an exclusive patent license to Phyxius michael.davis4@nih.gov.
Therapeutics, Inc., a start-up company incorporated as a C corporation under SUPPLEMENTARY INFORMATION:
the laws of the state of Delaware, to Intellectual Property practice the inventions covered by the HHS.
Dated: August 2, 2021.
Lawrence A. Tabak, Principal Deputy Director, National Institutes of Health.
NIH REF No.
National Institutes of Health,
patent estate listed in the SUPPLEMENTARY INFORMATION
ADDRESSES:
Filing Date
Issued Patent No.
Issue Date
Helical Peptides And Meth-
60/619,392
10/15/04
Helical Peptides And Meth-
PCT/US2005/
10/14/05
Helical Peptides And Meth-
2005295640
10/14/05
2005295640
11/10/11
Helical Peptides And Meth-
2584048
10/14/05
2584048
08/09/16
Helical Peptides And Meth-
05815961.7
10/14/05
1812474
05/26/10
Helical Peptides And Meth-
2007536912
10/14/05
5,091,679
09/21/12
Helical Peptides And Meth-
11/577,259
04/13/07
7,572,771
08/11/09
Helical Peptides And Meth-
12/497,443
07/02/09
8,071,746
12/06/11
Helical Peptides And Meth-
12/766,761
04/23/10
8,148,323
04/03/12
Helical Peptides And Meth-
05815961.7
10/14/05
1812474
05/26/10
Helical Peptides And Meth-
05815961.7
10/14/05
1812474
05/26/10
Helical Peptides And Meth-
05815961.7
10/14/05
1812474
05/26/10
Helical Peptides And Meth-
05815961.7
10/14/05
1812474
05/26/10
Helical Peptides And Meth-
05815961.7
10/14/05
1812474
05/26/10
Helical Peptides And Meth-
05815961.7
10/14/05
1812474
05/26/10
Helical Peptides And Meth-
13/407,132
02/28/12
8,835,378
09/16/14
licensed to the Government of the United States of America.
The prospective exclusive license territory may be worldwide and in fields of use that may be limited to use as a human therapeutic in patients with
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
atherosclerotic cardiovascular disease ASCVD, including patients undergoing cardiovascular surgery who are at risk of acute kidney injury.
The patents listed above cover an invention directed to peptides or
E:FRFM10AUN1.SGM
10AUN1
